by Montserrat
Garcia-Closas, Nilanjan Chatterjee
The Lancet Oncology: Comment, Volume 20 issue 4,
p.463-464, April 01 2019
Risk-assessment tools
are used in routine clinical practice to identify women at increased risk of
breast cancer and to inform counselling about lifestyle changes, genetic
testing, screening timing or modality, and eligibility for risk-reducing drugs
or surgery. In The Lancet Oncology, Mary Beth Terry and colleagues1 report a
comparative validation of four models—the Breast and Ovarian Analysis of
Disease Incidence and Carrier Estimation Algorithm model (BOADICEA), BRCAPRO,
the Breast Cancer Risk Assessment Tool (BCRAT), and the International Breast
Cancer Intervention Study model (IBIS)—used in clinical practice to provide
absolute risk estimates for breast cancer on the basis of different sets of
factors.
